What visual side effects can occur with GLP‑1 receptor agonists (e.g., exenatide, liraglutide, semaglutide)?

GLP-1 Receptor Agonists and Vision Side Effects

GLP-1 receptor agonists, particularly semaglutide, liraglutide, and dulaglutide, are associated with worsening diabetic retinopathy complications, especially in patients with pre-existing retinopathy who experience rapid A1C reduction. 1

Primary Vision Risk: Diabetic Retinopathy Complications

The most clinically significant visual side effect is rapidly worsening diabetic retinopathy, not new-onset retinopathy. This occurs through a well-established mechanism: rapid improvement in glucose control causes temporary worsening of existing retinopathy 2, 1, 2.

Risk Stratification by Patient History

High-risk patients (those with pre-existing diabetic retinopathy):

• Semaglutide: 8.2% developed retinopathy complications vs. 5.2% on placebo 3
• Absolute risk increase of approximately 3%

Low-risk patients (no known retinopathy history):

• Semaglutide: 0.7% vs. 0.4% on placebo 3
• Minimal absolute risk increase

The FDA label for semaglutide explicitly warns that patients with a history of diabetic retinopathy should be monitored for progression 3.

Mechanism: Rapid A1C Reduction, Not the Drug Itself

Critical distinction: Meta-analyses show no association between GLP-1 RAs and retinopathy per se, except through the association with rapid A1C reduction at 3-month and 1-year follow-up 2, 1. This means the risk is mediated by how quickly glucose improves, not by direct drug toxicity.

Agent-Specific Considerations

While the 2025 ADA guidelines note that liraglutide, semaglutide, and dulaglutide have been associated with "mildly worsening diabetic retinopathy" 1, the evidence is strongest for semaglutide, likely because it produces the most rapid and sustained glucose reductions 4.

Other Reported Visual Side Effects

Recent pharmacovigilance data (2024-2026) have identified additional signals, though these are less well-established:

• Visual impairment and blurred vision: Most frequently reported ocular adverse events across all GLP-1 RAs 5, 6
• Non-arteritic anterior ischemic optic neuropathy (NAION): Semaglutide showed disproportionate reporting (ROR 31-40) 6, though this remains hypothesis-generating
• Cataracts and glaucoma: Reported but meta-analyses show no increased risk compared to other antidiabetic medications 7

Important caveat: These newer signals come from spontaneous reporting systems (FAERS, VigiBase) which are susceptible to reporting bias and lack exposure denominators 5, 6. They are hypothesis-generating, not causal.

Mandatory Clinical Action: Pre-Treatment Eye Examination

Before initiating or intensifying GLP-1 RA therapy, assess retinopathy status 2, 1, 4. This is not optional—it's a guideline-level recommendation.

Screening Algorithm

1. All patients starting GLP-1 RAs: Document retinopathy status

   • If no recent eye exam: Obtain dilated fundoscopic examination
   • Type 2 diabetes: Should have had initial exam at diagnosis 1
   • Type 1 diabetes: Within 5 years of diagnosis 1

2. Patients with known retinopathy:

   • Ensure ophthalmology follow-up is established
   • Consider slower titration of GLP-1 RA to moderate A1C reduction speed
   • Monitor for progression more frequently than annually 1

3. Patients without retinopathy: Standard annual screening if no retinopathy on initial exam and glycemic goals met 1

Risk Mitigation Strategy

The key is controlling the rate of A1C reduction, not avoiding GLP-1 RAs entirely. Patients with proliferative retinopathy or severe non-proliferative retinopathy at baseline warrant particular caution with semaglutide 4.

Practical Approach

• Start at lowest dose and titrate gradually
• In high-risk patients, consider slower up-titration schedules
• Coordinate with ophthalmology for patients with established retinopathy
• The cardiovascular and metabolic benefits of GLP-1 RAs generally outweigh retinopathy risks when properly monitored 1

Common Pitfall to Avoid

Do not withhold GLP-1 RAs from patients with established cardiovascular disease or high CV risk solely due to retinopathy concerns. The mortality benefit is substantial 8. Instead, ensure appropriate ophthalmologic monitoring and consider the rate of glycemic improvement.

The 2018 ACC Expert Consensus explicitly states that risks and benefits should be "considered carefully" in patients with proliferative retinopathy, but does not contraindicate use—it mandates a recent eye examination prior to initiation 4.